Abstract

The CD4 receptor is the primary entry receptor for the human immunodeficiency virus. Besides this detrimental function, the CD4 receptor is crucial for positive selection and development of CD4+ T cells as well as for proper functioning of the immune system. During T cell activation, the CD4 receptor can fulfill an adhesion function, act as a signaling molecule and enhance the sensitivity of T cells to antigens. In addition, the CD4 receptor was suggested to be involved in differentiation towards the T helper 2 subset and in chemotaxis of T cells. In other types of immune cells, diverging functions are attributed to the CD4 receptor. The immunological importance of the CD4 receptor makes it an interesting target for immunosuppression. This is demonstrated by the immunosuppressive potential of several anti-CD4 monoclonal antibodies. These antibodies may have several modes of action, such as (1) inhibition of CD4+ T cell activation by steric hindrance of the CD4/major histocompatibility complex class II interaction resulting in antigen-specific tolerance, (2) down-modulation of the CD4 receptor, (3) switching from a pro-inflammatory T helper 1 to a more immunomodulatory T helper 2 type immune response, (4) induction of regulatory T cells and enhancement of their activity, or (5) delivery of a negative or attenuated signal into the CD4+ T cell. In addition, medicinal drugs that target CD4 are interesting alternatives for immunosuppressive treatment. The small molecule cyclotriazadisulfonamide (CADA) that down-modulates the CD4 receptor in a unique way by signal peptide-dependent inhibition of ER co-translational translocation is currently under investigation as a novel immunosuppressive drug.

Highlights

  • The cluster of differentiation 4 (CD4) receptor is a 55 kDa type I integral membrane protein consisting of four extracellular immunoglobulin-like domains, a spanning transmembrane region of 22 hydrophobic amino acids and a short cytoplasmic tail of 40 amino acids [1]

  • lymphocyte C-terminal Src kinase (Lck) targets the CD4 receptor to specialized lipid microdomains preferentially localized on microvilli, which are important in antigen recognition [9, 10]

  • Nondepleting anti-CD4 monoclonal antibodies may have several modes of action, such as (1) inhibition of CD4+ T cell activation by steric hindrance of the CD4/major histocompatibility complex (MHC) class II interaction that might result in antigen-specific tolerance, (2) down-modulation of the CD4 receptor, (3) switching from a proinflammatory Th1 to a more immunomodulatory Th2 type immune response, (4) induction of Treg cells and enhancement of their activity, or (5) delivery of a negative or attenuated signal into the CD4+ T cell [76]

Read more

Summary

Elisa Claeys and Kurt Vermeire*

KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, B-3000 Received: 23 August 2019 Accepted: 05 September 2019 Published: 09 September 2019

List of abbreviations
Introduction
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.